Region-of-Interest based sparse feature learning method for Alzheimer’s disease identification

Abstract

Background and ObjectiveIn recent years, some clinical parameters, such as the volume of gray matter (GM) and cortical thickness, have been used as anatomical features to identify Alzheimer’s disease (AD) from Healthy Controls (HC) in some feature-based machine learning methods. However, fewer image-based feature parameters have been proposed, which are equivalent to these clinical parameters, to describe the atrophy of regions-of-interest (ROIs) of the brain. In this study, we aim to extract effective image-based feature parameters to improve the diagnostic performance of AD with magnetic resonance imaging (MRI) data. MethodsA new subspace-based sparse feature learning method is proposed, which builds a union-of-subspace representation model to realize feature extraction and disease identification. Specifically, the proposed method estimates feature dimensions reasonably, at the same time, it protects local features for the specified ROIs of the brain, and realizes image-based feature extraction and classification automatically instead of computing the volume of GM or cortical thickness preliminarily. ResultsExperimental results illustrate the effectiveness and robustness of the proposed method on feature extraction and classification, which are based on the sampled clinical dataset from Peking University Third Hospital of China and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. The extracted image-based feature parameters describe the atrophy of ROIs of the brain well as clinical parameters but show better performance in AD identification than clinical parameters. Based on them, the important ROIs for AD identification can be identified even for correlated variables. ConclusionThe extracted features and the proposed identification parameters show high correlation with the volume of GM and the clinical mini-mental state examination (MMSE) score respectively. The proposed method will be useful in denoting the changes of cerebral pathology and cognitive function in AD patients.